Gennev Pricing History and Trajectory: What Women Are Actually Paying in 2024

What Gennev Is and How Its Business Model Has Changed

Gennev launched in 2016 as a subscription-based telehealth platform exclusively for women in perimenopause and menopause. The founding pitch was straightforward: give women direct access to OB-GYNs and health coaches who would not dismiss hot flashes as something to "just get through."

For its first several years, Gennev operated on a cash-pay membership model. An annual membership cost approximately $149 and unlocked discounted provider visits and health coaching. Individual OB-GYN video visits ran around $200-$250 on top of that fee. This model worked for women who could pay out of pocket, but it excluded a large share of the population, particularly women over 50 on fixed incomes who are statistically the most affected by menopause symptoms. The Menopause Society notes that menopause-related productivity loss and healthcare costs in the United States exceed $1.8 billion annually, meaning cost barriers have real downstream consequences.

The 2023 Acquisition and the Insurance Shift

In 2023, Unified Women's Healthcare acquired Gennev. Unified operates one of the largest networks of women's health practices in the country, which gave Gennev access to insurance credentialing infrastructure it had never had as a standalone startup. After the acquisition, Gennev began accepting major commercial insurance plans, Medicaid in select states, and Medicare Advantage plans in some markets.

This was a meaningful structural change, not a cosmetic rebrand. Before 2023, every dollar a patient spent at Gennev came directly from her wallet. After 2023, insurance could cover the provider visit portion, though prescription costs and health coaching remain largely out-of-pocket expenses.

What the Membership Model Actually Cost Over Time

| Period | Membership Fee | OB-GYN Visit | Coaching Session | |---|---|---|---| | 2016-2018 | ~$149/year | ~$200 | ~$75 | | 2019-2021 | ~$149/year | ~$225 | ~$85 | | 2021-2022 | Discontinued | ~$250 | ~$99 | | 2023-present | None | Insurance or ~$300-$350 cash | ~$99-$150 |

These figures are reconstructed from archived web data, user reports on Reddit and Menopause subreddits, and Gennev's own historical pricing pages. Gennev has not published a formal pricing history document.

What You Pay Today: A Breakdown by Insurance Status

The single biggest factor in your Gennev cost is whether your insurance covers telehealth OB-GYN visits. This varies by state, plan type, and the specific diagnosis code your provider uses.

If You Have Commercial Insurance

Post-2023, Gennev providers can bill your insurance for a telehealth OB-GYN evaluation the same way an in-person visit would be billed. Your cost is your plan's specialist copay, typically $30-$75 for most PPO plans. Women in high-deductible health plans (HDHPs) may pay $150-$300 until their deductible is met. Coverage for menopause-related diagnoses (ICD-10 N95.1 for menopausal and female climacteric states) is generally billable, though prior authorization requirements differ by insurer.

One area where insurance rarely helps: hormone therapy prescriptions filled through specialty compounding pharmacies, which Gennev uses for some custom HRT formulations. Compounded hormones are not FDA-approved finished drug products, and most commercial insurers do not cover them. A compounded estradiol-progesterone formulation can run $60-$150 per month cash pay.

If You Are Paying Cash

Cash-pay patients report OB-GYN visit costs of approximately $250-$350 per appointment as of mid-2024. Health coaching sessions (with registered dietitians or certified health coaches, not physicians) run $99-$150 per session. Gennev no longer lists bundled pricing prominently on its site, which makes comparison shopping harder than it should be.

Prescription Costs Through Gennev's Pharmacy Partners

Gennev prescribers can send prescriptions to:

• Your local pharmacy (your insurance applies normally for FDA-approved HRT products like estradiol patches, Bijuva, Annovera)
• Gennev's partner compounding pharmacies for custom formulations

Standard FDA-approved HRT through a retail pharmacy with GoodRx can be quite affordable. Generic estradiol patches (0.05 mg/0.1 mg twice weekly) run $20-$45 per month at major chains. Oral micronized progesterone (Prometrium 100 mg or 200 mg) costs $30-$80 monthly depending on dose and pharmacy. Women who are prescribed these standard formulations pay the same price whether the prescription comes from Gennev or their local OB-GYN, which is reassuring.

Is Gennev Legit? An Independent Assessment

Yes, with specific qualifications. Gennev employs licensed physicians (OB-GYNs and reproductive endocrinologists) and, after its acquisition, operates within Unified Women's Healthcare's credentialing and compliance infrastructure. Its providers are state-licensed in the jurisdictions where they practice.

A useful framework for evaluating any menopause telehealth platform has four dimensions: provider credentials, clinical protocols, prescription practices, and complaint patterns. Here is how Gennev scores on each.

Provider Credentials

Gennev's website states that its clinicians are board-certified OB-GYNs or women's health nurse practitioners with menopause-specific training aligned with The Menopause Society's (formerly NAMS) Menopause Practitioner certification. Not all Gennev providers hold the full NAMS NCMP credential, which requires a written examination and continuing education. Women who want a NAMS-certified provider should ask explicitly before booking.

The Menopause Society's 2023 position statement on menopause hormone therapy confirms that appropriately credentialed providers can safely manage HRT via telehealth for most women, with appropriate screening.

Clinical Protocols

Gennev uses a structured intake questionnaire covering symptom burden (typically the Menopause Rating Scale or MENQOL questionnaire), cardiovascular risk, personal and family history of breast cancer, history of blood clots, and current medications. This approach is consistent with ACOG Practice Bulletin No. 141 on management of menopausal symptoms, which recommends individualized risk assessment before initiating HRT.

Prescription Practices

Gennev prescribes both FDA-approved HRT and compounded hormones. The compounded hormone piece warrants caution. The FDA has repeatedly stated that compounded drugs are not FDA-approved and have not been evaluated for safety and efficacy in the same way approved products have. The Menopause Society's position is that FDA-approved hormone products should be used when available, with compounding reserved for documented medical necessity such as allergy to an excipient in a commercial product.

Women who receive a compounded HRT prescription from Gennev should ask their provider: "Is there an FDA-approved product that would achieve the same clinical goal?" That is a reasonable and medically appropriate question.

Complaint Patterns

The Better Business Bureau lists Gennev but shows it as not accredited as of July 2024. User complaints on the BBB site and across consumer review platforms (Trustpilot, Reddit's r/Menopause and r/Perimenopause) cluster around three themes:

1. Billing surprises after insurance adjudication, particularly when patients assumed insurance would cover more than it did
2. Difficulty reaching customer support after provider visits
3. Prescription delays when using Gennev's partner compounding pharmacies versus retail pharmacies

None of the documented complaints involve clinical harm, prescribing of controlled substances without appropriate evaluation, or regulatory action. There is no FDA warning letter against Gennev as of this writing.

Gennev vs. Competitors: Where It Sits on Price

The menopause telehealth market has expanded rapidly since 2020. Platforms including Midi Health, Alloy Women's Health, Evernow, and Hers now compete directly with Gennev. Here is a snapshot of how cash-pay visit costs compare:

| Platform | Cash Visit Cost | Insurance | Compounded HRT | |---|---|---|---| | Gennev | ~$300-$350 | Yes (post-2023) | Yes | | Midi Health | ~$0 (insurance only) | Yes | Limited | | Alloy | ~$99 initial / $85 follow-up | No | Yes | | Evernow | ~$99 first visit | No | Yes | | Hers | ~$49 initial assessment | No | Yes |

Gennev's cash-pay pricing sits at the higher end of this market. The insurance acceptance partially compensates for this, but only for women whose plans cover telehealth OB-GYN. For uninsured or underinsured women, Alloy or Evernow offer lower entry costs, though their provider credentials and clinical depth vary.

How Hormonal Status Affects What You Need from a Platform Like Gennev

Not all women in their 40s and 50s need the same type of care. Where you are in your menopause transition changes both what a platform should offer and what it will cost you.

Perimenopause (Typically Ages 40-51)

Perimenopause is the most diagnostically complex phase. Cycles are irregular, labs are often within normal range despite severe symptoms, and FSH levels fluctuate too much to be reliably diagnostic. A single FSH value does not confirm perimenopause according to ACOG, and a good telehealth platform should not be ordering FSH as a menopause "test" and billing you for it. Gennev's intake process accounts for symptom patterns rather than relying solely on lab values, which is clinically appropriate.

Women still having menstrual cycles who receive hormonal treatment from Gennev need to be counseled about contraception. Low-dose hormonal contraceptives (like the 20 mcg ethinyl estradiol pills or the levonorgestrel IUD) can manage perimenopausal symptoms AND provide contraception. Menopausal HRT doses are not contraceptive. This distinction matters: women over 40 remain at risk of unintended pregnancy until 12 consecutive months of amenorrhea, and telehealth platforms must address this clearly.

Menopause (12 Months of Amenorrhea)

This is Gennev's core demographic. Women in confirmed menopause are typically the best candidates for standard systemic HRT. Gennev's OB-GYN consult model is well-suited for initiating estradiol plus progestogen therapy, discussing the Women's Health Initiative data in its current context, and titrating dose based on symptom response.

The WHI original 2002 findings scared millions of women off HRT unnecessarily. The reanalysis published in JAMA in 2017 and subsequent data have clarified that for healthy women under 60 or within 10 years of menopause onset, the benefit-risk profile of estrogen-based HRT is generally favorable. A good Gennev consult should cover this nuance.

Post-Menopause (More Than 5 Years Post-Menopause)

Women who are more than a decade past menopause onset face a different risk calculus for initiating HRT for the first time. Cardiovascular risk and breast density considerations shift. Gennev's telehealth model is appropriate for continuing established HRT in this group but may be insufficient for women with complex cardiac histories or those considering initiating HRT for the first time after age 65. In those cases, referral to an in-person menopause specialist or cardiologist may be warranted.

Pregnancy, Lactation, and Contraception: What Gennev's Hormone Products Mean for You

This section is mandatory for any platform prescribing hormone products. HRT formulations used in menopause care are not appropriate for use in pregnancy or in women actively trying to conceive.

Estrogen and Progestogen Products: Pregnancy Safety

Systemic estrogens and progestins are FDA Pregnancy Category X in their menopause HRT formulations, meaning known or potential fetal risk outweighs any possible benefit. They must not be taken during pregnancy. If you are perimenopausal and still having cycles, you must confirm you are not pregnant before starting HRT. A urine pregnancy test before initiation is standard.

Progesterone supplementation at specific doses (200-400 mg) is used in fertility treatment and early pregnancy support, but this is a distinct clinical context from menopausal HRT. Gennev does not market itself as a fertility platform. If you are trying to conceive, Gennev is not the right service for your primary reproductive care.

Lactation

Women who are breastfeeding are typically not simultaneously in menopause, but postpartum women can experience significant estrogen deficiency and GSM (genitourinary syndrome of menopause-like symptoms) while lactating. Low-dose vaginal estrogen (estradiol vaginal cream, Vagifem, Imvexxy) is considered compatible with breastfeeding by most lactation authorities given minimal systemic absorption. Systemic estrogen should generally be avoided while breastfeeding as it may reduce milk supply. A postpartum woman experiencing vaginal dryness or dyspareunia while nursing should discuss low-dose local vaginal estrogen specifically with her provider.

Contraception Requirements

Any perimenopausal woman receiving systemic HRT from Gennev must have an explicit contraception conversation with her provider. HRT does not suppress ovulation. The options typically recommended are:

• Levonorgestrel IUD (also manages heavy perimenopausal bleeding)
• Progestogen-only pill (no estrogen interaction concerns)
• Barrier methods
• Permanent contraception if family is complete

Combined hormonal contraceptives (CHCs) containing ethinyl estradiol are generally avoided in women over 40 who smoke, have migraines with aura, or have cardiovascular risk factors per WHO Medical Eligibility Criteria.

Who Gennev Is Right For and Who Should Look Elsewhere

Right for You If:

• You are in perimenopause or menopause and your primary insurer covers telehealth OB-GYN visits
• You want a clinician who will take hot flashes, sleep disruption, and brain fog seriously rather than dismissing them
• You are comfortable with video visits and digital prescription management
• You are an established HRT user looking to continue care conveniently
• You have no complex cardiovascular, oncology, or coagulation history that requires in-person workup

Consider Other Options If:

• You are uninsured and cannot afford $300+ cash-pay visits (look at Alloy or Evernow at lower entry cost)
• You need a NAMS-certified menopause practitioner specifically (ask Gennev directly about credential verification before booking)
• You are in confirmed menopause with more than 10 years since your last period and considering initiating HRT for the first time (see an in-person specialist)
• You have a personal or strong family history of hormone-sensitive breast cancer (telehealth is appropriate for information gathering but in-person oncology consultation should anchor your decision)
• You are actively trying to conceive (Gennev is not a fertility platform; use ASRM-accredited REI practices)
• Your primary complaint is genitourinary and you would benefit from pelvic floor physical therapy referral, which Gennev cannot provide

What to Watch as Gennev's Pricing Evolves

The 2023 Unified Women's Healthcare acquisition has financial implications that have not fully materialized in pricing yet. Unified is a large private-equity-backed healthcare network. Historical patterns in PE-backed telehealth suggest that after an initial period of market-share building (often reflected in stable or lower pricing), platforms typically raise prices as they capture a stable subscriber base.

Women who join Gennev now should document their current pricing in writing, including any quoted cash-pay rates or insurance cost estimates. If you receive a compounded hormone prescription, ask annually whether an FDA-approved equivalent has become available that your insurance might now cover. The field for FDA-approved menopause therapies has broadened with newer products like Veozah (fezolinetant), the first non-hormonal neurokinin B antagonist approved for vasomotor symptoms in May 2023, which is a standard commercial product that insurance may cover.

The Menopause Society's 2023 position statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." This clinical consensus supports the core premise of what Gennev offers, but the platform's value depends on whether its pricing and access model serves you specifically.

Midlife women deserve menopause care that is thorough, evidence-based, and priced transparently. Ask Gennev for a written cost estimate before your first appointment, including what will and will not be billed to insurance, and confirm your provider's specific menopause credentials. Then compare that against at least one competitor platform before deciding.